Expanded Access to Investigational Medicines
CRISPR Therapeutics is focused on the development and commercialization of novel therapies to treat hemoglobinopathies, cancer, diabetes, and other diseases.
At this time, CRISPR Therapeutics does not provide access to investigational products outside of clinical trials. We encourage patients to participate in clinical trials of our investigational therapies whenever possible, because clinical trials are designed, conducted, and monitored to ensure that the safety and efficacy are appropriately evaluated before they are submitted to regulatory agencies for review with the intent to make them more broadly available to patients.
You and your health care provider may learn more about our clinical trials by going to the pipeline section of our website, or visiting www.clinicaltrials.gov and searching for CRISPR Therapeutics.
If you are a health care provider who is interested in learning more about one of our investigational therapies, or a physician with questions about participation in one of our clinical trials, please submit a request to firstname.lastname@example.org. The company will acknowledge questions as soon as possible, usually within 5 business days of receipt.
If applicable, this website will be updated with hyperlinks to the relevant expanded access information on www.clinicaltrials.gov upon activation. CRISPR Therapeutics reserves the right to revise this expanded access policy at any time.
You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.